These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258 [TBL] [Abstract][Full Text] [Related]
30. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Kallio J; Lindberg R; Huupponen R; Iisalo E Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585 [TBL] [Abstract][Full Text] [Related]
31. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590 [TBL] [Abstract][Full Text] [Related]
32. Association between the oxidative polymorphism and early onset of Parkinson's disease. Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946 [TBL] [Abstract][Full Text] [Related]
33. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768 [TBL] [Abstract][Full Text] [Related]
34. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Ashforth EI; Palmer JL; Bye A; Bedding A Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461 [TBL] [Abstract][Full Text] [Related]
35. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Meier PJ; Mueller HK; Dick B; Meyer UA Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386 [TBL] [Abstract][Full Text] [Related]
36. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320 [TBL] [Abstract][Full Text] [Related]
37. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822 [TBL] [Abstract][Full Text] [Related]
38. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]